1stOncology™: Cancer Intelligence Service – Page 13316 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

On August 28, 2019 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that Neurocrine Biosciences management will present at the following investor conferences (Press release, Neurocrine Biosciences, AUG 28, 2019, View Source [SID1234539085]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Matt Abernethy, Chief Financial Officer, will present at the Baird 2019 Global Healthcare Conference at 8:30 a.m. ET on Wednesday, Sept. 4, 2019, in New York.
Kevin Gorman, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Healthcare Conference at 11:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York.
The live presentations will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company

On August 28, 2019 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC) reported receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular’s remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how (Press release, ImmunoCellular Therapeutics, AUG 28, 2019, View Source [SID1234539084]).

As previously disclosed, the aggregate purchase price of the assets was $1,000,000, payable by a private biotechnology company ("Purchaser") in two payments. The first upfront payment of $500,000 was received by ImmunoCellular upon the initial closing of the asset sale transaction on May 8, 2019, and was non-refundable. The second, or continuation, payment of $500,000, which has been received, was dependent upon the satisfactory outcome of certain discussions between the Purchaser and the US Food and Drug Administration.

With the successful completion of the asset sale, ImmunoCellular plans to continue to pursue additional strategic alternatives, including a potential reverse merger with a private company seeking an expedited route to the public markets. The Company welcomes inquiries by parties interested in such a potential collaboration. As of August 23, 2019, ImmunoCellular’s balance sheet reflected a cash position of approximately $2.0 million with no debt or other liabilities other than ongoing trade payables related to its limited operations. The Company cannot guarantee that any ongoing or future strategic discussions will be successfully concluded.

Haemonetics to Present at the 17th Morgan Stanley’s Annual Global Healthcare Conference

On August 28, 2019 Haemonetics Corporation (NYSE: HAE) reported that Chris Simon, President and CEO, will present at Morgan Stanley’s Annual Global Healthcare Conference in New York, NY on Monday, September 9, 2019 at 11:05am Eastern time (Press release, Haemonetics, AUG 28, 2019, View Source [SID1234539083]).

The public may access Mr. Simon’s presentation live via webcast and subsequent replay at: https://cc.talkpoint.com/morg007/090919b_js/?entity=135_MNCOIVN

Triple-S Management Corporation to Participate in the 2019 Wells Fargo Healthcare Conference

On August 28, 2019 Triple-S Management Corporation (NYSE: GTS) reported that its President and Chief Executive Officer Roberto García-Rodríguez, and its EVP and Chief Financial Officer Juan José Román-Jiménez will participate in a fireside chat at the 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at the Westin Copley Place in Boston, Massachusetts (Press release, Triple-S Management, AUG 28, 2019, https://www.prnewswire.com/news-releases/triple-s-management-corporation-to-participate-in-the-2019-wells-fargo-healthcare-conference-300908463.html [SID1234539082]). The fireside chat will begin at 1:15 PM Eastern Time.

Investors and interested parties may listen to the webcast of the fireside chat by visiting the Company’s investor relations website at www.triplesmanagement.com under the "News and Events" section at the appropriate time.

Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference

On August 28, 2019 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York (Press release, Quest Diagnostics, AUG 28, 2019, View Source [SID1234539081]). Stephen Rusckowski, Chairman, President and CEO will discuss the company’s vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Monday, September 9, 2019 at 11:40 a.m. Eastern Time.

The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until October 9, 2019.